Answers are grounded in this paper and cite their sources.
Background and purpose: The principal cause of cardiomyocyte dysfunction and necrosis resulting from Ischemia/Reperfusion (I/R) injury is the production and release of Reactive Oxygen Species (ROS) from damaged mitochondria.Mitochondrial ROS-mediated oxidation of cellular proteins and lipids disrupts both cellular metabolism and organelle integrity, leading to depletion of ATP stores and an increase in intracellular calcium (Ca 2+ ) levels.Thus, attenuation of I/R-induced ROS production has been a therapeutic strategy to salvage damaged cardiomyocytes and thereby limit cardiac functional impairment and infarct size [1].Previous studies have tested the effectiveness of mitochondrial-targeted antioxidants.Mitoquinone (MitoQ) was effective in reducing I/R injury when given only prior to prolonged ischemia, while Szeto-Schiller (SS)-31 was effective when given either prior to ischemia or at the beginning of reperfusion.This study was undertaken to determine whether these agents are effective in limiting myocardial and hindlimb I/R injury when given during the first 5min of reperfusion only, and thereby support the premise that mitochondrial damage underlies reperfusion-induced cell death during the initial minutes of reperfusion.Experimental approach: Male Sprague-Dawley rats (275-325 g) were randomized into myocardial or hindlimb I/R groups.Isolated, retrogradely perfused hearts were subjected to global I(30 min)/R(45 min).Hearts were treated with MitoQ (1-20 µM), SS-31 (10-100 µM), or plasma (control) added to the perfusate at the onset of reperfusion and was assessed for cardiac function and infarct size.In the hindlimb experiments, either hydrogen peroxide (H 2 O 2 ) or Nitric Oxide (NO) sensors were placed randomly in both the right and left femoral veins of the same animal.One limb was subjected to I(30 min)/R(45 min) by reversibly clamping the femoral artery/vein, while the other limb served as a sham.The animal received an intravenous (i.v.) bolus of either MitoQ (1.8 mg kg -1 ), SS-31 (2.5 mg kg -1 ), or saline (control) at the beginning of reperfusion.The difference in blood H 2 O 2 or NO between the femoral vein of ischemic and sham limbs in each animal was continuously measured to assess the effects of the drugs. Key results:In the myocardial I/R model, MitoQ and SS-31 given upon reperfusion significantly improved cardiac function and reduced infarct size compared to untreated control hearts.In the hindlimb I/R model, elevations in blood H 2 O 2 levels and reductions in blood NO, both indices of elevated ROS, were significantly attenuated by both MitoQ and SS-31 given upon reperfusion compared to saline treated control animals. Conclusion and implications:The results indicate that mitochondrial-derived ROS is a major contributor to reperfusion injury and that MitoQ and SS-31 work expeditiously to attenuate ROS in that both agents improve cardiac function and limit infarct size when administered only at the onset of reperfusion.The data suggest that MitoQ or SS-31 would be an effective adjuvant to reduce ischemia reperfusion injury in acute myocardial infarction patients receiving percutaneous coronary intervention, thrombolytic therapy, or undergoing coronary by-pass surgery.
No takes yet. Share an insight, caveat, or question.
A 2019 study studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: